Lumos Pharma to Participate in September Investor Conferences
September 02, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
August 05, 2021 08:00 ET
|
Lumos Pharma, Inc.
• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board •...
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
August 03, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that...
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
August 02, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current...
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
July 26, 2021 16:18 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach,...
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
July 22, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma Announces Clinical Updates
July 20, 2021 16:01 ET
|
Lumos Pharma, Inc.
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 monthsOraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be...
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
June 28, 2021 08:00 ET
|
Lumos Pharma, Inc.
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas, June 28, 2021 (GLOBE...
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
May 19, 2021 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
May 13, 2021 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...